FDAMA Proposed List of Agents Not to be Compounded due to Withdrawal for Safety/Efficacy Concerns
Download in electronic PDF format for $75
Abstract: The US Food and Drug Administration has proposed that drug products listed in the table provided here be included on the list of drug products withdrawn or removed from the market because they have been found to be unsafe or ineffective. Therefore, compounding a drug product on this list would not be covered by the exemption provided in Section 503A(a) of the Federal Food and Drug Administration Modernization Act of 1997. The list originally appeared in the October 8, 1998, Federal Register (63[195]:54083-54087). Listings are mostly alphabetical. Reasons for withdrawal and withdrawal dates are also provided.
Related Keywords:
Safety, Efficacy
| Related Articles from IJPC |
Title/Author
(Click for Abstract / Details / Purchase) |
Issue/Page
View/Buy |
FDAMA Proposed List of Agents Not to be Compounded due to Withdrawal for Safety/Efficacy Concerns
Allen Loyd V Jr
|
Jan/Feb 1999
Pg. 25-29
|
Safety Standards in Pharmaceutical Compounding, Part 3: Fire Safety
Allen W Chris, Greeson Nicole MH, Mixon William
|
Nov/Dec 2020
Pg. 451-458
|
Efficacy and Tolerability of Compounded Bioidentical Hormone Replacement Therapy
Vigesaa Kristy A, Downhour Nathan P, Chui Michelle A, Cappellini Linda, Musil John D, McCallian Dennis J
|
Jul/Aug 2004
Pg. 313-319
|
Wetting and/or Solubilizing Agents, Featured Excipient:
Allen Loyd V Jr
|
Jul/Aug 2001
Pg. 310-312
|
Safety and Efficacy Studies, Pharmacy Education, and the NASEM Report on Compounded Topical Pain Creams
Allen Loyd V Jr
|
Sep/Oct 2020
Pg. 356
|
Safety Standards in Pharmaceutical Compounding, Part 1: The Occupational Safety and Health Administration
Greeson Nicole MH, Mixon William, Allan W Chris
|
Jul/Aug 2020
Pg. 270-276
|
Safety Standards in Pharmaceutical Compounding, Part 2: A Closer Look at Agency Information, Oversight, and Assistance
Greeson Nicole MH, Mixon William, Allan W Chris
|
Sep/Oct 2020
Pg. 371-379
|
Basics of Compounding: The Revised "Not to Compound List"
Allen Loyd V Jr
|
Jan/Feb 2015
Pg. 57-58
|
Efficacy and Clinical Value of Commonly Used Ingredients in Pain Management Compounds: A Literature Review
Beshay Sarah M, Rivera Gerard, Balthasar Jan, Florea Naomi
|
Mar/Apr 2024
Pg. 111-116
|
Efficacy and Clinical Value of Commonly Used Ingredients in Pain Management Compounds: A Literature Review
Beshay Sarah M, Rivera Gerard, Balthasar Jan, Florea Naomi
|
Jul/Aug 2015
Pg. 295-300
|
Complying with Occupational Safety and Health Administration Regulations: A Guide for Compounding Pharmacists
Mixon Bill, Nain John
|
May/Jun 2013
Pg. 182-190
|
Compounding Enclosures: Ensuring Safety During the Preparation of Sterile and Nonsterile Formulations
Ashe Krystina, Baskett Dustin
|
Sep/Oct 2018
Pg. 387-398
|
How to Develop and Maintain a Hazardous Drug List
Dillon L Rad
|
May/Jun 2019
Pg. 182-186
|
Quality Control: (Material) Safety Data Sheets
Allen Loyd V Jr
|
Mar/Apr 2017
Pg. 118-124
|
Safety for Employees in the Compounding Work Area
Allen Loyd V Jr
|
Jan/Feb 2002
Pg. 60-61
|
Quality Control Analytical Methods: A Growing Codependency: Compounding Pharmacy and Safety
Prince Bryan, Lundeval Jeremy
|
Nov/Dec 2013
Pg. 485-489
|
Determining Whether a Substance is Legal to Compound with Under Section 503A of the FDCA
Cabaleiro Joe
|
Sep/Oct 2021
Pg. 358-362
|
Efficacy and Clinical Value of Commonly Compounded Hormone Replacement Therapy: A Literature Review
Beshay Sarah M, Rivera Gerard, Balthasar Jan, Florea Naomi
|
Jan/Feb 2015
Pg. 6-12
|
The "Lists": What Do They Mean?
Voliva John
|
Nov/Dec 2016
Pg. 477-479
|
Basics of Compounding: The "Negative" List
Allen Loyd V
|
Jul/Aug 2015
Pg. 311-313
|
| Return to Top |
